PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Nichi-Iko’s Xarelto Generic Adds VTE Use
Nichi-Iko said on January 30 that it has earned additional indications for its generic version of the anticoagulant Xarelto (rivaroxaban), expanding use into venous thromboembolism (VTE) in both adults and children.The product is now newly indicated for the treatment of…
To read the full story
Related Article
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- Xarelto AG Logs 9.6 Billion Yen on NHI Basis in April-September: Qol
November 10, 2025
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
BUSINESS
- Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
- Vyepti Could Expand Migraine Treatment Options: Japanese Expert
October 26, 2026
- Zeria to Buy German Asacol Manufacturing Partner
October 26, 2026
- Otsuka’s IgAN Drug Voyxact Cuts Kidney Event Risk by 97%
October 26, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…